
LOXO
Other · Other
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2018
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 8, 2018 | Time not confirmed | -0.88 | -0.89 | -1.1% |
| Aug 9, 2018 | Time not confirmed | -0.54 | -0.39 | +27.8% |
| May 8, 2018 | Time not confirmed | -0.72 | -0.12 | +83.3% |
| Feb 1, 2018 | Time not confirmed | -1.13 | -0.69 | +38.9% |
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such…